HSBC AKT.ANL. 03/25 MRK/ DE000HS5CSN0 /
24/01/2025 21:40:12 | Chg.+0.040 | Bid21:59:06 | Ask21:59:06 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
95.760EUR | +0.04% | 95.560 Bid Size: 20,000 |
95.760 Ask Size: 20,000 |
MERCK KGAA O.N. | 150.00 EUR | 28/03/2025 | Call |
GlobeNewswire
03/06/2024
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29/05/2024
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
29/05/2024
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
GlobeNewswire
07/05/2024
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05/2024
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
04/03/2024
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
14/12/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
17/10/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA